Details
Stereochemistry | ACHIRAL |
Molecular Formula | C27H39N3O |
Molecular Weight | 421.6181 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)C1=CC=CC(C(C)C)=C1NC(=O)NCC2(CCCC2)C3=CC=C(C=C3)N(C)C
InChI
InChIKey=PKKNCEXEVUFFFI-UHFFFAOYSA-N
InChI=1S/C27H39N3O/c1-19(2)23-10-9-11-24(20(3)4)25(23)29-26(31)28-18-27(16-7-8-17-27)21-12-14-22(15-13-21)30(5)6/h9-15,19-20H,7-8,16-18H2,1-6H3,(H2,28,29,31)
Molecular Formula | C27H39N3O |
Molecular Weight | 421.6181 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Nevanimibe (also known as PD-132301 and ATR101) is an acetyl-CoA C-acyltransferase (ACAT1) inhibitor. Millendo Therapeutics is currently advancing the development of nevanimibe for the treatment of two orphan adrenal diseases: classic congenital adrenal hyperplasia (CAH) and endogenous Cushing's syndrome (CS). Both of these diseases are associated with an overactive adrenal cortex causing excess steroid production. Millendo believes that nevanimibe represents an adrenal-specific approach that will address these diseases through the reduction of adrenal steroid production. Millendo is currently conducting Phase 2 clinical trial to assess the safety and efficacy of nevanimibe in subjects with endogenous Cushing’s syndrome and for the treatment of adult CAH.
Originator
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Morphogenesis of a zone-specific adrenocortical cytotoxicity in guinea pigs administered PD 132301-2, an inhibitor of acyl-CoA:cholesterol acyltransferase. | 1993 |
|
Subacute toxicity of a novel inhibitor of acyl-CoA: cholesterol acyltransferase in beagle dogs. | 1993 Feb |
|
Toxicologic effects of a novel acyl-CoA:cholesterol acyltransferase inhibitor in cynomolgus monkeys. | 1994 Sep-Oct |
|
Biochemical alterations in guinea pig adrenal cortex following administration of PD 132301-2, an inhibitor of acyl-CoA:cholesterol acyltransferase. | 1995 Feb 17 |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT03669549
During the 12-week treatment period, all subjects will begin dosing with nevanimibe HCl (PD-132301) 1000 mg BID and be dose titrated to 1500 mg BID and then 2000 mg BID based upon the 17-OHP response that will be assessed every 4 weeks.
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 02:14:00 GMT 2023
by
admin
on
Sat Dec 16 02:14:00 GMT 2023
|
Record UNII |
VK9OS8R205
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
497315
Created by
admin on Sat Dec 16 02:14:00 GMT 2023 , Edited by admin on Sat Dec 16 02:14:00 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
EF-118
Created by
admin on Sat Dec 16 02:14:00 GMT 2023 , Edited by admin on Sat Dec 16 02:14:00 GMT 2023
|
PRIMARY | |||
|
131679
Created by
admin on Sat Dec 16 02:14:00 GMT 2023 , Edited by admin on Sat Dec 16 02:14:00 GMT 2023
|
PRIMARY | |||
|
DTXSID10928286
Created by
admin on Sat Dec 16 02:14:00 GMT 2023 , Edited by admin on Sat Dec 16 02:14:00 GMT 2023
|
PRIMARY | |||
|
C170216
Created by
admin on Sat Dec 16 02:14:00 GMT 2023 , Edited by admin on Sat Dec 16 02:14:00 GMT 2023
|
PRIMARY | |||
|
100000177353
Created by
admin on Sat Dec 16 02:14:00 GMT 2023 , Edited by admin on Sat Dec 16 02:14:00 GMT 2023
|
PRIMARY | |||
|
10892
Created by
admin on Sat Dec 16 02:14:00 GMT 2023 , Edited by admin on Sat Dec 16 02:14:00 GMT 2023
|
PRIMARY | |||
|
VK9OS8R205
Created by
admin on Sat Dec 16 02:14:00 GMT 2023 , Edited by admin on Sat Dec 16 02:14:00 GMT 2023
|
PRIMARY | |||
|
133825-80-6
Created by
admin on Sat Dec 16 02:14:00 GMT 2023 , Edited by admin on Sat Dec 16 02:14:00 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
INHIBITOR -> TARGET |
|
||
|
SALT/SOLVATE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|